Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tavo-103 by Tavotek Biotherapeutics for Chronic Inflammation: Likelihood of Approval
Tavo-103 is under clinical development by Tavotek Biotherapeutics and currently in Phase I for Chronic Inflammation. According to GlobalData, Phase...